Recombinant ESAT-6-like proteins provoke protective immune responses against invasive Staphylococcus aureus disease in a murine model

Infection and Immunity

Volumn 83, Issue 1, 2015, Pages 339-345

  Zhang, Bao Zhong ^a   Hua, Yan Hong ^a   Yu, Bin ^a   Lau, Candy Choi Yi ^a   Cai, Jian Piao ^a   Zheng, Song Yue ^a   Yam, Wing Cheong ^a   Kao, Richard Yi Tsun ^a   Sze, Kong Hung ^a   Zheng, Bo Jian ^a   Yuen, Kwok Yung ^a   Huang, Jian Dong ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY SECRETORY ANTIGENIC TARGET 6; ESXA PROTEIN; PROTEIN ANTIBODY; RECOMBINANT PROTEIN; SAESXB PROTEIN; UNCLASSIFIED DRUG; VACCINE; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; RECOMBINANT VACCINE; STAPHYLOCOCCUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PROTEIN SECRETION; PROTEIN TARGETING; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SURVIVAL RATE; TH1 CELL; TH17 CELL; VACCINATION; ANIMAL; BACTEREMIA; BAGG ALBINO MOUSE; BLOOD; GENETICS; IMMUNOLOGY; STAPHYLOCOCCAL INFECTIONS; SURVIVAL;

ANIMALS; ANTIBODIES, BACTERIAL; BACTEREMIA; BACTERIAL PROTEINS; FEMALE; MICE, INBRED BALB C; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS; TH1 CELLS; TH17 CELLS; VACCINES, SYNTHETIC;

EID: 84919482577     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02498-14     Document Type: Article

References (44)

1. Blot S, Vandewoude K, Colardyn F. 1998. Staphylococcus aureus infections. N Engl J Med 339:2025-2026. http://dx.doi.org/10.1056/NEJM199812313392716.
2. Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, Pfaller MA, Sheppard D, Twombley J, French PP, Herwaldt LA. 2002. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 346:1871-1877. http://dx.doi.org/10.1056/NEJMoa003069.
3. Gould IM. 2005. The clinical significance of methicillin-resistant Staphylococcus aureus. J Hosp Infect 61:277-282. http://dx.doi.org/10.1016/j.jhin.2005.06.014.
4. Abrahamian FM, Moran GJ. 2007. Methicillin-resistant Staphylococcus aureus infections. N Engl J Med 357:2090. http://dx.doi.org/10.1056/NEJMc072407.
5. Schaffer AC, Lee JC. 2008. Vaccination and passive immunisation against Staphylococcus aureus. Int J Antimicrob Agents 32(Suppl 1):S71-S78. http://dx.doi.org/10.1016/j.ijantimicag.2008.06.009.
6. Stranger-Jones YK, Bae T, Schneewind O. 2006. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 103: 16942-16947. http://dx.doi.org/10.1073/pnas.0606863103.
7. Bubeck Wardenburg J, Schneewind O. 2008. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205:287-294. http://dx.doi.org/10.1084/jem.20072208.
8. Yin RL, Li C, Yang ZT, Zhang YJ, Bai WL, Li X, Yin RH, Liu H, Liu S, Yang Q, Cao YG, Zhang NS. 2009. Construction and immunogenicity of a DNA vaccine containing clumping factor A of Staphylococcus aureus and bovine IL18. Vet Immunol Immunopathol 132:270-274. http://dx.doi.org/10.1016/j.vetimm.2009.05.012.
9. Jonsson IM, Mazmanian SK, Schneewind O, Verdrengh M, Bremell T, Tarkowski A. 2002. On the role of Staphylococcus aureus sortase and sortase-catalyzed surface protein anchoring in murine septic arthritis. J Infect Dis 185:1417-1424. http://dx.doi.org/10.1086/340503.
10. Inskeep TK, Stahl C, Odle J, Oakes J, Hudson L, Bost KL, Piller KJ. 2010. Oral vaccine formulations stimulate mucosal and systemic antibody responses against staphylococcal enterotoxin B in a piglet model. Clin Vaccine Immunol 17:1163-1169. http://dx.doi.org/10.1128/CVI.00078-10.
11. Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O. 2010. Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J Exp Med 207:1863-1870. http://dx.doi.org/10.1084/jem.20092514.
12. Arrecubieta C, Matsunaga I, Asai T, Naka Y, Deng MC, Lowy FD. 2008. Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J Infect Dis 198:571-575. http://dx.doi.org/10.1086/590210.
13. Kim HK, DeDent A, Cheng AG, McAdow M, Bagnoli F, Missiakas DM, Schneewind O. 2010. IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 28:6382-6392. http://dx.doi.org/10.1016/j.vaccine.2010.02.097.
14. Roth DM, Senna JP, Machado DC. 2006. Evaluation of the humoral immune response in BALB/c mice immunized with a naked DNA vaccine anti-methicillin-resistant Staphylococcus aureus. Genet Mol Res 5:503-512.
15. Gaudreau MC, Lacasse P, Talbot BG. 2007. Protective immune responses to a multi-geneDNAvaccine against Staphylococcus aureus. Vaccine 25:814-824. http://dx.doi.org/10.1016/j.vaccine.2006.09.043.
16. Fattom A, Fuller S, Propst M, Winston S, Muenz L, He D, Naso R, Horwith G. 2004. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. Vaccine 23:656-663. http://dx.doi.org/10.1016/j.vaccine.2004.06.043.
17. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R. 2002. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 346: 491-496. http://dx.doi.org/10.1056/NEJMoa011297.
18. Menzies BE, Kernodle DS. 1994. Site-directed mutagenesis of the alphatoxin gene of Staphylococcus aureus: role of histidines in toxin activity in vitro and in a murine model. Infect Immun 62:1843-1847.
19. Spellberg B, Ibrahim AS, Yeaman MR, Lin L, Fu Y, Avanesian V, Bayer AS, Filler SG, Lipke P, Otoo H, Edwards JE, Jr. 2008. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun 76:4574-4580. http://dx.doi.org/10.1128/IAI.00700-08.
20. Brown EL, Dumitrescu O, Thomas D, Badiou C, Koers EM, Choudhury P, Vazquez V, Etienne J, Lina G, Vandenesch F, Bowden MG. 2009. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infect 15:156-164. http://dx.doi.org/10.1111/j.1469-0691.2008.02648.x.
21. Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, McNeely T, Noble L, Brown MJ, Zorman JK, Wang XM, Pancari G, Fan H, Isett K, Burgess B, Bryan J, Brownlow M, George H, Meinz M, Liddell ME, Kelly R, Schultz L, Montgomery D, Onishi J, Losada M, Martin M, Ebert T, Tan CY, Schofield TL, Nagy E, Meineke A, Joyce JG, Kurtz MB, Caulfield MJ, Jansen KU, McClements W, Anderson AS. 2006. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 74:2215-2223. http://dx.doi.org/10.1128/IAI.74.4.2215-2223.2006.
22. DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Polak M, Jung E, Millard D, Schelonka R, Eyal F, Morris A, Kapik B, Roberson D, Kesler K, Patti J, Hetherington S. 2007. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 151:260-265. http://dx.doi.org/10.1016/j.jpeds.2007.04.060.
23. Patti JM. 2004. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 22(Suppl 1):S39-S43. http://dx.doi.org/10.1016/j.vaccine.2004.08.015.
24. Benjamin DK, Schelonka R, White R, Holley HP, Bifano E, Cummings J, Adcock K, Kaufman D, Puppala B, Riedel P, Hall B, White J, Cotton CM. 2006. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol 26:290-295. http://dx.doi.org/10.1038/sj.jp.7211496.
25. Rupp ME, Holley HP, Jr, Lutz J, Dicpinigaitis PV, Woods CW, Levine DP, Veney N, Fowler VG, Jr. 2007. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 51:4249-4254. http://dx.doi.org/10.1128/AAC.00570-07.
26. Proctor RA. 2012. Challenges for a universal Staphylococcus aureus vaccine. Clin Infect Dis 54:1179-1186. http://dx.doi.org/10.1093/cid/cis033.
27. Biswas L, Biswas R, Nerz C, Ohlsen K, Schlag M, Schafer T, Lamkemeyer T, Ziebandt AK, Hantke K, Rosenstein R, Gotz F. 2009. Role of the twin-arginine translocation pathway in Staphylococcus. J Bacteriol 191:5921-5929. http://dx.doi.org/10.1128/JB.00642-09.
28. Schneewind O, Missiakas DM. 2012. Protein secretion and surface display in Gram-positive bacteria. Philos Trans R Soc Lond B Biol Sci 367: 1123-1139. http://dx.doi.org/10.1098/rstb.2011.0210.
29. Burts ML, Williams WA, DeBord K, Missiakas DM. 2005. EsxA and EsxB are secreted by an ESAT-6-like system that is required for the pathogenesis of Staphylococcus aureus infections. Proc Natl Acad Sci U S A 102:1169-1174. http://dx.doi.org/10.1073/pnas.0405620102.
30. Galan JE, Cossart P. 2005. Host-pathogen interactions: a diversity of themes, a variety of molecular machines. Curr Opin Microbiol 8:1-3. http://dx.doi.org/10.1016/j.mib.2004.12.015.
31. Korea CG, Balsamo G, Pezzicoli A, Merakou C, Tavarini S, Bagnoli F, Serruto D, Unnikrishnan M. 2014. Staphylococcal Esx proteins modulate apoptosis and release of intracellular Staphylococcus aureus during infection in epithelial cells. Infect Immun 82:4144-4153. http://dx.doi.org/10.1128/IAI.01576-14.
32. Pallen MJ. 2002. The ESAT-6/WXG100 superfamily-and a new Grampositive secretion system? Trends Microbiol 10:209-212. http://dx.doi.org/10.1016/S0966-842X(02)02345-4.
33. Ulrichs T, Munk ME, Mollenkopf H, Behr-Perst S, Colangeli R, Gennaro ML, Kaufmann SH. 1998. Differential T cell responses to Mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors. Eur J Immunol 28:3949-3958. http://dx.doi.org/10.1002/(SICI)1521-4141(199812)28:123949::AID-IMMU39493.0.CO;2-4.
34. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, Fu Y, French SW, Edwards JE, Jr, Spellberg B. 2009. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 5:e1000703. http://dx.doi.org/10.1371/journal.ppat.1000703.
35. Holland SM. 2010. Chronic granulomatous disease. Clin Rev Allergy Immunol 38:3-10. http://dx.doi.org/10.1007/s12016-009-8136-z.
36. Roos D, Kuhns DB, Maddalena A, Roesler J, Lopez JA, Ariga T, Avcin T, de Boer M, Bustamante J, Condino-Neto A, Di Matteo G, He J, Hill HR, Holland SM, Kannengiesser C, Koker MY, Kondratenko I, van Leeuwen K, Malech HL, Marodi L, Nunoi H, Stasia MJ, Ventura AM, Witwer CT, Wolach B, Gallin JI. 2010. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis 45:246-265. http://dx.doi.org/10.1016/j.bcmd.2010.07.012.
37. McCarthy AJ, Lindsay JA. 2010. Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiol 10:173. http://dx.doi.org/10.1186/1471-2180-10-173.
38. Sorensen AL, Nagai S, Houen G, Andersen P, Andersen AB. 1995. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun 63:1710-1717.
39. Chatterjee S, Dwivedi VP, Singh Y, Siddiqui I, Sharma P, Van Kaer L, Chattopadhyay D, Das G. 2011. Early secreted antigen ESAT-6 of Mycobacterium tuberculosis promotes protective T helper 17 cell responses in a toll-like receptor-2-dependent manner. PLoS Pathog 7:e1002378. http://dx.doi.org/10.1371/journal.ppat.1002378.
40. Pearce EJ, Caspar P, Grzych JM, Lewis FA, Sher A. 1991. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J Exp Med 173:159-166. http://dx.doi.org/10.1084/jem.173.1.159.
41. Misstear K, McNeela EA, Murphy AG, Geoghegan JA, O'Keeffe KM, Fox J, Chan K, Heuking S, Collin N, Foster TJ, McLoughlin RM, Lavelle EC. 2014. Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus. J Infect Dis 209:1479-1484. http://dx.doi.org/10.1093/infdis/jit636.
42. Miller LS, Cho JS. 2011. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol 11:505-518. http://dx.doi.org/10.1038/nri3010.
43. Minegishi Y, Karasuyama H. 2009. Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency. Int Immunol 21:105-112. http://dx.doi.org/10.1093/intimm/dxn134.
44. Kumar P, Chen K, Kolls JK. 2013. Th17 cell based vaccines in mucosal immunity. Curr Opin Immunol 25:373-380. http://dx.doi.org/10.1016/j.coi.2013.03.011.